Diana Giannarelli
#147,171
Most Influential Person Now
Researcher
Diana Giannarelli's AcademicInfluence.com Rankings
Diana Giannarellicomputer-science Degrees
Computer Science
#7474
World Rank
#7871
Historical Rank
Artificial Intelligence
#3058
World Rank
#3104
Historical Rank
Database
#4525
World Rank
#4704
Historical Rank
Download Badge
Computer Science
Diana Giannarelli's Degrees
- PhD Computer Science Stanford University
- Masters Artificial Intelligence University of California, Berkeley
Similar Degrees You Can Earn
Why Is Diana Giannarelli Influential?
(Suggest an Edit or Addition)Diana Giannarelli's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. (2009) (1319)
- Prevention of VTE in orthopedic surgery patients (2013) (635)
- Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. (2005) (429)
- Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers (2015) (408)
- Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. (2002) (353)
- Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. (2013) (324)
- Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy (2014) (307)
- Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. (2000) (290)
- Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. (2003) (265)
- Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab (2018) (260)
- Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. (2012) (258)
- Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma (2014) (240)
- Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. (1999) (232)
- Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. (2016) (208)
- Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients (2015) (187)
- Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. (2018) (183)
- Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. (2015) (176)
- Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. (2018) (163)
- Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials (2008) (161)
- Clinical Significance of αvβ3 Integrin and Intercellular Adhesion Molecule-1 Expression in Cutaneous Malignant Melanoma Lesions (1997) (160)
- Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. (2012) (159)
- Can patient selection for bladder preservation be based on response to chemotherapy? (2003) (157)
- Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. (2011) (155)
- Benefit of taxanes as adjuvant chemotherapy for early breast cancer (2006) (153)
- Effectiveness of continuous wound infusion of 0.5% ropivacaine by On-Q pain relief system for postoperative pain management after open nephrectomy. (2008) (141)
- Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution (2021) (140)
- Zoledronic-Acid-Induced Circulating Level Modifications of Angiogenic Factors, Metalloproteinases and Proinflammatory Cytokines in Metastatic Breast Cancer Patients (2005) (132)
- Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: Italian multicenter study S.I.T.I.L.O. (2011) (131)
- Radiation therapy in the management of symptomatic bone metastases: the effect of total dose and histology on pain relief and response duration. (1998) (130)
- Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use (2012) (129)
- Chordoma: clinical characteristics, management and prognosis of a case series of 25 patients (2010) (128)
- Vitamin E neuroprotection for cisplatin neuropathy (2010) (127)
- Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab (2019) (125)
- Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. (1998) (125)
- Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme (2013) (123)
- Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion (1989) (121)
- Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer (2008) (116)
- Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin's disease: eight-year update of an Italian prospective randomized study. (1992) (115)
- Prognostic relevance of altered Fas (CD95)‐system in human breast cancer (2000) (114)
- Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine (2021) (112)
- Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. (2015) (111)
- Diagnostic and prognostic value of peritoneal immunocytology in gastric cancer. (1998) (104)
- Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis. (2011) (101)
- The responsiveness of bone metastases to radiotherapy: the effect of site, histology and radiation dose on pain relief. (1989) (100)
- Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non–Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial (2019) (99)
- Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. (2019) (99)
- Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. (2005) (98)
- Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program (2019) (98)
- A Randomized Trial of Goal Directed vs Standard Fluid Therapy in Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (2015) (97)
- Treatment of peritoneal carcinomatosis with intent to cure (2000) (97)
- Prognostic factors influencing cisplatin‐induced emesis. Definition and validation of a predictive logistic model (1989) (96)
- Second primary cancer following Hodgkin's disease: updated results of an Italian multicentric study. (1991) (91)
- Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer? (2009) (88)
- Molecular analyses and prognostic relevance of HPV in head and neck tumours. (2007) (86)
- Gemcitabine‐based combinations for inoperable pancreatic cancer: Have we made real progress? (2007) (85)
- Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy) (2011) (83)
- Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions. (1997) (82)
- Adjuvant chemotherapy in muscle‐invasive bladder carcinoma (2006) (81)
- Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer (2019) (80)
- A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer. (2009) (78)
- Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide. (2003) (76)
- Outcome and tolerability of topiramate in brain tumor associated epilepsy (2007) (74)
- Prognostic factors for chemotherapy response and survival using combination chemotherapy as initial treatment of advanced head and neck squamous cell cancer. (1989) (73)
- Italian Nivolumab Expanded Access Program in Nonsquamous Non–Small Cell Lung Cancer Patients: Results in Never‐Smokers and EGFR‐Mutant Patients (2018) (71)
- Supracricoid partial laryngectomies after radiation failure: A multi‐institutional series (2008) (71)
- Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme. (2018) (69)
- Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype. (2012) (69)
- Local recurrence after curative resection for colorectal cancer: Frequency, risk factors and treatment (1991) (68)
- Secondary analyses from a randomized clinical trial: age as the key prognostic factor in endometrial carcinoma. (2014) (66)
- Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy (2015) (65)
- The Time Course of Diagnostic Delay in Inflammatory Bowel Disease Over the Last Sixty Years: An Italian Multicentre Study (2017) (65)
- Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab (2017) (64)
- The course of cancer related fatigue up to ten years in early breast cancer patients: What impact in clinical practice? (2017) (64)
- Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer. (2004) (63)
- Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real‐world results from an expanded access programme (2018) (63)
- A phase III randomized study on the sequencing of radiotherapy and chemotherapy in the conservative management of early-stage breast cancer. (2006) (63)
- Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials (2010) (61)
- Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. (2006) (61)
- Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial (2014) (60)
- The effect of extend of caval resection in the treatment of inferior vena cava leiomyosarcoma. (1997) (58)
- Differentiating chronic lymphocytic leukemia from monoclonal B-lymphocytosis according to clinical outcome: on behalf of the GIMEMA chronic lymphoproliferative diseases working group (2011) (58)
- Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer. (2003) (57)
- Short- and long-term effects of 186Re-1,1-hydroxyethylidene diphosphonate in the treatment of painful bone metastases. (2000) (57)
- Obesity may hamper SARS-CoV-2 vaccine immunogenicity (2021) (56)
- Neoadjuvant m‐vac (methotrexate, vinblastine, doxorubicin, and cisplatin) for infiltrating transitional cell carcinoma of the bladder (1993) (55)
- Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations (2018) (54)
- Do immune checkpoint inhibitors need new studies methodology? (2018) (54)
- The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients (2016) (54)
- Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies. (2008) (54)
- Taxanes as primary chemotherapy for early breast cancer (2008) (53)
- Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL) (2020) (53)
- Blockage of interleukin-1β with canakinumab in patients with Covid-19 (2020) (53)
- Nerve-sparing surgery in 302 resectable rectosigmoid cancer patients: Genitourinary morbidity and 10-year survival (1994) (53)
- Increased serum levels of matrix metalloproteinase‐9 predict clinical outcome of patients with early B‐cell chronic lymphocytic leukaemia (2003) (52)
- Prolonged gemcitabine infusion in advanced non–small cell lung carcinoma (2003) (51)
- Results of Bard BTA test in monitoring patients with a history of transitional cell cancer of the bladder. (1997) (51)
- Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. (2012) (48)
- High serum IL‐2 levels are predictive of prolonged survival in multiple myeloma (1990) (48)
- Tumor progression in human malignant melanoma is associated with changes in α6/β1 laminin receptor (1991) (47)
- Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trials. (2009) (46)
- Taxanes with anthracyclines as first‐line chemotherapy for metastatic breast carcinoma (2005) (46)
- Neoadjuvant chemotherapy in previously untreated patients with advanced head and neck squamous cell cancer (1988) (45)
- Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial (2019) (45)
- 120 peritoneal carcinomatoses from colorectal cancer treated with peritonectomy and intra-abdominal chemohyperthermia: a S.I.T.I.L.O. multicentric study. (2006) (45)
- Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting. (2016) (44)
- Peritonectomy and hyperthermic antiblastic perfusion in the treatment of peritoneal carcinomatosis. (2000) (44)
- Survival of hereditary non-polyposis colorectal cancer patients compared with sporadic colorectal cancer patients (2008) (44)
- Acute leukaemia in patients treated for Hodgkin's disease (1984) (44)
- Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients (2017) (44)
- Clinical features and outcome of familial chronic lymphocytic leukemia. (2006) (44)
- Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants? (2006) (44)
- Escalated M-VAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with advanced urothelial tract tumors. (1993) (44)
- Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder. (1999) (44)
- The Prognostic Role of Circulating Tumor Cells (CTC) in High‐risk Non–muscle‐invasive Bladder Cancer (2017) (44)
- Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials (2019) (43)
- Factors affecting difficult peripheral intravenous cannulation in adults: a prospective observational study (2017) (43)
- Cognitive rehabilitation training in patients with brain tumor-related epilepsy and cognitive deficits: a pilot study (2015) (41)
- Altered Expression of FAS System Is Related to Adverse Clinical Outcome in Stage I-II Breast Cancer Patients Treated with Adjuvant Anthracycline-Based Chemotherapy (2004) (41)
- Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer. (2019) (41)
- A prospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer (1989) (40)
- The utility of a prognostic index for predicting time to first treatment in early chronic lymphocytic leukemia: the GIMEMA experience (2010) (40)
- Propolis in the prevention of oral mucositis in breast cancer patients receiving adjuvant chemotherapy: A pilot randomised controlled trial (2017) (40)
- Fixed dose‐rate gemcitabine infusion as first‐line treatment for advanced‐stage carcinoma of the pancreas and biliary tree (2005) (39)
- Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status. (2014) (39)
- Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide? (2006) (39)
- Cell surface overexpression of galectin-3 and the presence of its ligand 90k in the blood plasma as determinants in colon neoplastic lesions. (2004) (38)
- Reference Charts for Fetal Corpus Callosum Length (2014) (37)
- Laparoscopic and robotic partial nephrectomy without renal ischaemia for tumours larger than 4 cm: perioperative and functional outcomes (2012) (37)
- T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer. (2018) (37)
- The long-term prognostic value of survivin expressing circulating tumor cells in patients with high-risk non-muscle invasive bladder cancer (NMIBC) (2017) (36)
- Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study. (2000) (36)
- Adjuvant chemotherapy (AC) with cisplatin + gemcitabine (CG) versus chemotherapy (CT) at relapse (CR) in patients (pts) with muscle-invasive bladder cancer (MIBC) submitted to radical cystectomy (RC). An Italian multicenter randomised phase III trial (2008) (36)
- INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study. (2018) (36)
- Clinical impact of anti‐epidermal growth factor receptor monoclonal antibodies in first‐line treatment of metastatic colorectal cancer (2012) (36)
- Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study (2014) (35)
- PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab (2017) (35)
- Chronic non-cancer pain in primary care: an Italian cross-sectional study (2020) (34)
- Vitamin E neuroprotection against cisplatin ototoxicity: Preliminary results from a randomized, placebo‐controlled trial (2016) (34)
- Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single Institution (2021) (34)
- Clinical Evaluation of the Use of Exemestane as Further Hormonal Therapy after Nonsteroidal Aromatase Inhibitors in Postmenopausal Metastatic Breast Cancer Patients (2007) (34)
- First-line treatment with epirubicin and vinorelbine in metastatic breast cancer. (2002) (34)
- Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group (2017) (34)
- Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population. (2019) (34)
- The first report on coronavirus disease 2019 (COVID-19) vaccine refusal by patients with solid cancer in Italy: Early data from a single-institute survey (2021) (33)
- Elevated serum levels of soluble CD44 can identify a subgroup of patients with early B‐cell chronic lymphocytic leukemia who are at high risk of disease progression (2001) (33)
- Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma. (2016) (33)
- Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials (2011) (33)
- Epidemiology of Chronic Pain in the Latium Region, Italy: A Cross-Sectional Study on the Clinical Characteristics of Patients Attending Pain Clinics. (2019) (33)
- Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series (2016) (33)
- “Triple positive” early breast cancer: an observational multicenter retrospective analysis of outcome (2016) (33)
- New aromatase inhibitors as second‐line endocrine therapy in postmenopausal patients with metastatic breast carcinoma (2005) (32)
- Postoperative infections after cytoreductive surgery and HIPEC for peritoneal carcinomatosis: proposal and results from a prospective protocol study of prevention, surveillance and treatment. (2014) (32)
- Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study (2018) (32)
- Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients. (2002) (31)
- IgD multiple myeloma a descriptive report of 17 cases: survival and response to therapy (2012) (31)
- Open Radical Cystectomy versus Robot-Assisted Radical Cystectomy with Intracorporeal Urinary Diversion: Early Outcomes of a Single-Center Randomized Controlled Trial (2022) (31)
- Genitourinary tumors, non-prostate (2012) (31)
- Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia (2021) (31)
- Hyperthermic antiblastic perfusion with alpha tumor necrosis factor and doxorubicin for the treatment of soft tissue limb sarcoma in candidates for amputation: results of a phase I study. (1999) (31)
- Prognostic value of bone marrow histology in chronic lymphocytic leukemia. A study of 335 untreated cases from a single institution. (1994) (31)
- Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials (2006) (31)
- Molecular analysis of sarcomeric and non-sarcomeric genes in patients with hypertrophic cardiomyopathy. (2016) (31)
- Uterine Papillary Serous, Clear Cell, and Poorly Differentiated Endometrioid Carcinomas: A Comparative Study (2011) (31)
- Inflatable Penile Prosthesis Placement, Scratch Technique and Postoperative Vacuum Therapy as a Combined Approach to Definitive Treatment of Peyronie's Disease (2018) (30)
- The application of hyperthermia in regional chemotherapy. (1998) (30)
- The first report on Covid-19 vaccine refusal by cancer patients in Italy: early data from a single-institute survey (2021) (30)
- Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma (2017) (30)
- Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program. (2019) (29)
- Comparison of Patient-reported Health-related Quality of Life Between Open Radical Cystectomy and Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion: Interim Analysis of a Randomised Controlled Trial. (2021) (29)
- Serum angiogenin is not elevated in patients with early B‐cell chronic lymphocytic leukemia but is prognostic factor for disease progression (2004) (29)
- Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: a high-activity, dose-dense weekly regimen for advanced breast cancer. (1999) (29)
- Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme (2009) (29)
- A novel LAMP2 mutation associated with severe cardiac hypertrophy and microvascular remodeling in a female with Danon disease: a case report and literature review. (2016) (28)
- Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer (2013) (28)
- Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers (2021) (28)
- HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis (2020) (27)
- Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study (2016) (27)
- Early Onset of SARS-COV-2 Antibodies after First Dose of BNT162b2: Correlation with Age, Gender and BMI (2021) (27)
- Gemcitabine at fixed dose-rate in patients with advanced soft tissue sarcomas: a mono-institutional phase II study (2008) (27)
- Italian external and multicentric validation of the MD Anderson Cancer Center nomogram and prognostic index for chronic lymphocytic leukaemia patients: analysis of 1502 cases (2014) (26)
- Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia (2010) (26)
- A phase 2 single-arm study with tremelimumab at an optimized dosing schedule in second-line mesothelioma patients. (2014) (26)
- Oncological outcome and prognostic factors in malignant parotid tumours. (2014) (26)
- DNA ploidy, proliferative index, and epidermal growth factor receptor: expression and prognosis in patients with gastric cancers. (1995) (26)
- Perampanel in patients with brain tumor-related epilepsy in real-life clinical practice: a retrospective analysis (2019) (26)
- A gender-based score system predicts the clinical outcome of patients with early B-cell chronic lymphocytic leukemia (2005) (26)
- Endoscopic follow-up in resected colorectal cancer patients. (2000) (26)
- Cryotherapy reduces oral mucositis and febrile episodes in myeloma patients treated with high-dose melphalan and autologous stem cell transplant: a prospective, randomized study (2017) (25)
- FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort (2013) (25)
- FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma. (2021) (25)
- Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials. (2014) (25)
- An integrated psychological strategy for advanced colorectal cancer patients (2006) (24)
- Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. (2013) (24)
- Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme (2013) (24)
- A randomized phase II study comparing sequential versus simultaneous chemo-radiotherapy in patients with unresectable locally advanced squamous cell cancer of the head and neck. (1994) (24)
- Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases (2019) (24)
- Targeting targeted agents: open issues for clinical trial design (2009) (24)
- Multivariate analysis of a tissue CEA, TPA, and CA 19.9 quantitative study in colorectal cancer patients (1989) (24)
- Vitamin D insufficiency predicts time to first treatment (TFT) in early chronic lymphocytic leukemia (CLL). (2012) (24)
- Corrigendum: Baseline neutrophils and derived neutrophilto-lymphocyte ratio: Prognostic relevance in metastatic melanoma patients receiving ipilimumab. [Ann Oncol 27, (2016), (732-738)] doi:10.1093/annonc/mdw016. (2016) (24)
- Use of discriminant analysis to assess disease activity in pulmonary tuberculosis with a panel of specific and nonspecific serum markers. (1994) (23)
- Accelerated chemotherapy with high-dose epirubicin and cyclophosphamide plus r-met-HUG-CSF in locally advanced and metastatic breast cancer. (1995) (23)
- A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study (2011) (23)
- Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients (2006) (23)
- Early post-operative MRI: correlation with progression-free survival and overall survival time in malignant gliomas. (2006) (23)
- Overcoming resistance to chronomodulated 5-fluorouracil and folinic acid by the addition of chronomodulated oxaliplatin in advanced colorectal cancer patients (2000) (23)
- Adherence to Oral Administration of Endocrine Treatment in Patients With Breast Cancer: A Qualitative Study (2016) (23)
- Long‐term survival in locally advanced oral cavity cancer: An analysis of patients treated with neoadjuvant cisplatin‐based chemotherapy followed by surgery (2005) (23)
- Minimal Residual Disease and Survival Outcomes in Patients With Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis. (2019) (23)
- LBA45 First report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo Immuno and Targeted therapy study) (2020) (22)
- Phenotypic changes of p53, HER2, and FAS system in multiple normal tissues surrounding breast cancer (2005) (22)
- Transurethral resection of the prostate and metastatic prostate cancer (1991) (22)
- Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter? (2017) (22)
- Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy (2020) (22)
- Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade (2020) (22)
- A preliminary European Liver and Intestine Transplant Association-European Liver Transplant Registry study on informed recipient consent and extended criteria liver donation. (2013) (22)
- BRAF Mutant NSCLC and Immune Checkpoint Inhibitors: Results From a Real-World Experience. (2019) (22)
- Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data (2018) (22)
- LBA40 SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: A phase II randomized study (2021) (22)
- Hereditary hemochromatosis type 1 phenotype modifiers in Italian patients. The controversial role of variants in HAMP, BMP2, FTL and SLC40A1 genes. (2015) (22)
- Double‐blind randomized phase III study comparing a mixture of natural agents versus placebo in the prevention of acute mucositis during chemoradiotherapy for head and neck cancer (2017) (22)
- Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: sensitivity analysis of randomized trials. (2015) (21)
- Effective Control of CMF‐Related Emesis with High‐Dose Dexamethasone: Results of a Double‐Blind Crossover Trial with Metoclopramide and Placebo (1989) (21)
- State of the art about influenza vaccination for advanced cancer patients receiving immune checkpoint inhibitors: When common sense is not enough. (2019) (21)
- Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer (2014) (21)
- Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: Meta-analysis of randomized trials (2010) (21)
- Flow cytometric analysis of ploidy in colorectal cancer: a multicentric experience. (1993) (21)
- Patterns of care of brain tumor-related epilepsy. A cohort study done in Italian Epilepsy Center (2017) (20)
- Perampanel Confirms to Be Effective and Well-Tolerated as an Add-On Treatment in Patients With Brain Tumor-Related Epilepsy (PERADET Study) (2020) (20)
- Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients (2020) (20)
- Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: pooled-analysis of 8794 patients. (2006) (20)
- The introduction of the absolute risk for the detection of fetal aneuploidies in the first-trimester screening (2017) (20)
- Prognostic role of inguinal lymphadenectomy in vulvar squamous carcinoma: younger and older patients should be equally treated. A prospective study and literature review. (2015) (20)
- Metastases to the cerebellum. Results and prognostic factors in a consecutive series of 44 operated patients (2008) (20)
- Gemcitabine and Cisplatin in the Treatment of Elderly Patients with Advanced Non-Small Cell Lung Cancer: Impact of Comorbidities on Safety and Efficacy Outcome (2005) (20)
- Definitive radiation therapy for localized prostatic adenocarcinoma. (1991) (19)
- Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database (2018) (19)
- Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation (2011) (19)
- Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma (2009) (19)
- Development and external validation of nomograms predicting disease-free and cancer-specific survival after radical cystectomy (2015) (19)
- Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial (2022) (19)
- Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy (2012) (19)
- Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival (2020) (19)
- The role of multiploidy as unfavorable prognostic variable in colorectal cancer. (1998) (19)
- Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice. (2016) (19)
- Assessing time to first treatment in early chronic lymphocytic leukemia (CLL): a comparative performance analysis of five prognostic models with inclusion of CLL-international prognostic index (CLL-IPI) (2017) (18)
- Does adjuvant chemotherapy improve survival in non small cell lung cancer (NSCLC)? A pooled-analysis of 6494 patients in 12 studies, examining survival and magnitude of benefit (2005) (18)
- Perampanel in brain tumor‐related epilepsy: Observational pilot study (2020) (18)
- Comparing two methods of meta-analysis in clinical research - individual patient data-based (IPD) and literature-based abstracted data (AD) methods: Analyzing five oncology issues involving more than 10,000 patients in randomized clinical trials (RCTs) (2007) (18)
- Effects of exogenous progesterone on fetal nuchal translucency: an observational prospective study. (2015) (17)
- Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients (2015) (17)
- Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice. (2015) (17)
- Long-Term Results of a Randomized Trial on the Sequencing of Radiotherapy and Chemotherapy in Breast Cancer (2011) (16)
- Elaboration of a nomogram to predict non sentinel node status in breast cancer patients with positive sentinel node, intra-operatively assessed with one step nucleic acid amplification method (2015) (16)
- Hyperthermic antiblastic perfusion for the treatment of soft tissue limb sarcoma. (1992) (16)
- Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials. (2014) (16)
- Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases (2021) (16)
- External validation on a prospective basis of a nomogram for predicting the time to first treatment in patients with chronic lymphocytic leukemia (2013) (16)
- HER-2/neu oncogene amplification and chromosome 17 aneusomy in endometrial carcinoma: correlation with oncoprotein expression and conventional pathological parameters. (2003) (16)
- Oral Hygiene Care in Patients With Advanced Disease: An Essential Measure to Improve Oral Cavity Conditions and Symptom Management (2019) (16)
- Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study (2021) (16)
- Prevalence of diabetes and diabetic macular edema in patients undergoing senile cataract surgery in Italy: The DIabetes and CATaract study (2019) (16)
- Breast cancer and timing of surgery during menstrual cycle: a 5‐year analysis of 248 premenopausal women (1999) (16)
- Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin’s lymphomas (2021) (16)
- COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial (2021) (16)
- Neoadjuvant M-VAC (methotrexate, vinblastine, adriamycin, and cisplatin) chemotherapy and bladder preservation for muscle-infiltrating transitional cell carcinoma of the bladder. (1995) (15)
- Doxorubicin in isolation limb perfusion in the treatment of advanced limb soft tissue sarcoma. (2003) (15)
- Effect of vaginally administered DHA fatty acids on pregnancy outcome in high risk pregnancies for preterm delivery: a double blinded randomised controlled trial. (2013) (15)
- Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort. (2013) (15)
- Serum levels of syndecan-1 in B-cell chronic lymphocytic leukemia: Correlation with the extent of angiogenesis and disease-progression risk in early disease (2006) (14)
- The Italian experience on interferon as maintenance treatment in multiple myeloma: ten years after. (1998) (14)
- Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study. (2020) (14)
- [Peritonectomy and chemohyperthermia in the treatment of peritoneal carcinomatosis: learning curve]. (2005) (14)
- Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients (2013) (14)
- A Phase II Trial of Docetaxel and Vinorelbine in Patients with Advanced Breast Cancer Previously Treated with Anthracyclines (2008) (14)
- Add-on of aripiprazole improves outcome in clozapine-resistant schizophrenia (2011) (14)
- Unavailability of thymidine kinase does not preclude the use of German comprehensive prognostic index: results of an external validation analysis in early chronic lymphocytic leukemia and comparison with MD Anderson Cancer Center model (2016) (14)
- Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer. (2005) (14)
- Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia: A Serologic and Cellular Study (2021) (14)
- Prognostic relevance of serum levels and cellular expression of adiponectin in B-cell chronic lymphocytic leukemia (2008) (14)
- Quality of life and disability of chronic non-cancer pain in adults patients attending pain clinics: A prospective, multicenter, observational study. (2020) (14)
- Chronic lymphocytic leukemia international prognostic index (CLL-IPI) in patients receiving chemoimmuno or targeted therapy: a systematic review and meta-analysis (2018) (13)
- Gemcitabine treatment of experimental C6 glioma: the effects on cell cycle and apoptotic rate. (2006) (13)
- Association between Anemia and Multiple Sclerosis (2015) (13)
- Comparison of 18F-FDG PET/CT Criteria for the Prediction of Therapy Response and Clinical Outcome in Patients With Metastatic Melanoma Treated With Ipilimumab and PD-1 Inhibitors. (2020) (13)
- Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non–Small Cell Lung Cancer With a PD-L1 Expression ≥50% (2020) (13)
- Single-agent vinorelbine in pretreated breast cancer patients: comparison of two different schedules. (2004) (13)
- Prevalence and risk factors of delirium in the intensive care unit: An observational study. (2020) (13)
- Melanoma and other skin tumors (2012) (13)
- Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis. (2015) (13)
- Extended criteria liver donation and transplant recipient consent: the European experience. (2011) (13)
- Supracricoid partial laryngectomy for radiorecurrent laryngeal cancer: a systematic review of the literature and meta-analysis (2018) (13)
- Lonidamine as a potentiating agent of the FAC regimen in the treatment of advanced breast cancer. Results of a multicentric randomized clinical study (1994) (13)
- Cutaneous response to irritants (2003) (13)
- Effect of Brivaracetam on Efficacy and Tolerability in Patients With Brain Tumor-Related Epilepsy: A Retrospective Multicenter Study (2020) (13)
- INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2) (2021) (13)
- Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG (2020) (13)
- A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer (2007) (13)
- Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: preliminary results from the prospective observational Vax-On study (2021) (13)
- Meeting report: Vitiligo Global Issues Consensus Conference Workshop “Outcome measurement instruments” and Vitiligo International Symposium, Rome, Nov 30–Dec 3rd (2017) (13)
- Hyperthermic antiblastic perfusion in the treatment of local recurrence or "in-transit" metastases of limb melanoma. (1992) (12)
- Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists (2020) (12)
- Time to First Tumor Progression as Outcome Predictor of a Second Trasuzumab‐Based Therapy beyond Progression in HER‐2 Positive Metastatic Breast Cancer 1 (2010) (12)
- Tumor progression in human malignant melanoma is associated with changes in alpha 6/beta 1 laminin receptor. (1991) (12)
- Improving cancer patients’ knowledge about totally implantable access port: a randomized controlled trial (2016) (12)
- Prevalence, incidence and associated factors of pressure injuries in hospices: A multicentre prospective longitudinal study. (2020) (12)
- Social distress among medical oncologists and other healthcare professionals during the first wave of COVID-19 pandemic in Italy (2021) (12)
- DNA ploidy, proliferative index and EGF-R status in 130 cases of resected gastric cancer--a multivariate analysis. (1997) (12)
- Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter study. (2017) (12)
- Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II study (2008) (12)
- Serum level of CD26 predicts time to first treatment in early B‐chronic lymphocytic leukemia (2009) (12)
- Interferon-β therapy and risk of thrombocytopenia in multiple sclerosis patients (2015) (11)
- Prognostic value of HER2 and progesterone receptor expression in endometrial carcinoma with positive peritoneal washing. (2007) (11)
- Low-molecular-weight heparin versus oral anticoagulant therapy for the long-term treatment of symptomatic venous thromboembolism: Is there any difference in cancer-related mortality? (2005) (11)
- Intrapatient comparison of single-agent epirubicin with or without lonidamine in metastatic breast cancer. (1995) (11)
- High activity of salvage treatment with biweekly paclitaxel-gemcitabine combination in heavily pretreated breast cancer patients. (2006) (11)
- Serum insulin‐like growth factor is not elevated in patients with early B‐cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression (2006) (11)
- Neoadjuvant Sequential Docetaxel Followed by High‐Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial (2016) (11)
- A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. (2012) (11)
- Inflammatory Markers and Procalcitonin Predict the Outcome of Metastatic Non-Small-Cell-Lung-Cancer Patients Receiving PD-1/PD-L1 Immune-Checkpoint Blockade (2021) (11)
- Activity and Safety of Bevacizumab Plus Fotemustine for Recurrent Malignant Gliomas (2014) (11)
- Bolusvs. continuous hepatic arterial infusion of cisplatin plus intravenous 5-fluorouracil chemotherapy for unresectable colorectal metastases (1994) (10)
- Chronic lymphocytic leukemia international prognostic index: a systematic review and meta-analysis. (2018) (10)
- Fluorouracil, doxorubicin, and cyclophosphamide versus fluorouracil, doxorubicin, and cyclophosphamide plus lonidamine for the treatment of advanced breast cancer: a multicentric randomized clinical study. (1991) (10)
- Zonisamide in Brain Tumor–Related Epilepsy: An Observational Pilot Study (2017) (10)
- Reliability of six prognostic models to predict time‐to‐first‐treatment in patients with chronic lymphocytic leukaemia in early phase (2017) (10)
- Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy (2018) (10)
- Reduction of serum IGF-I levels in patients affected with Monoclonal Gammopathies of undetermined significance or Multiple Myeloma. Comparison with bFGF, VEGF and K-ras gene mutation (2009) (10)
- Detection of Helicobacter pylori carriers by discriminant analysis of urea and pH levels in gastric juices. (1991) (10)
- Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: Implications for post-progression and conditional survival. (2016) (10)
- Humoral and T-cell immune response after three doses of mRNA SARS-CoV-2 vaccines in fragile patients: the Italian VAX4FRAIL study (2022) (10)
- Adherence to hormone therapy in women with breast cancer: a quantitative study. (2016) (10)
- Development and validation of a patient-reported outcome tool to assess cancer-related financial toxicity in Italy: a protocol (2019) (10)
- Inequity in palliative care service full utilisation among patients with advanced cancer: a retrospective Cohort study (2020) (10)
- Phase I–II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclines (2011) (10)
- Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib (2021) (10)
- Early Progression in Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Treated with Pembrolizumab in First-Line Setting: A Prognostic Scoring System Based on Clinical Features (2021) (10)
- Comparison 18F-FDG-PET/CT criteria for prediction of therapy response and clinical outcome in patients with metastatic melanoma treated with ipilimumab and PD-1 inhibitors (2019) (10)
- Randomised phase II study of methotrexate (MTX) versus methotrexate plus lonidamine (MTX + LND) in recurrent and/or metastatic carcinoma of the head and neck. (1994) (10)
- Low Frequency of Acute Pancreatitis in Hospitalized COVID-19 Patients (2021) (10)
- Estrogen treatment in infertile women with premature ovarian insufficiency in transitional phase: a retrospective analysis (2018) (10)
- The role of hyperthermic perfusion in the treatment of tumors of the extremities. (1990) (9)
- Leukotoxicity after moderately Hypofractionated radiotherapy versus conventionally fractionated dose escalated radiotherapy for localized prostate Cancer: a secondary analysis from a randomized study (2019) (9)
- Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis (2021) (9)
- The Effectiveness of the Sport "Dragon Boat Racing" in Reducing the Risk of Lymphedema Incidence: An Observational Study. (2018) (9)
- Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients (2015) (9)
- KRAS mutation and DNA repair and synthesis genes in non-small-cell lung cancer. (2018) (9)
- Interphase cytogenetics of bladder cancer progression: relationship between aneusomy, DNA ploidy pattern, histopathology, and clinical outcome (2000) (9)
- Laser-assisted hatching of human embryos: may two alternative approaches (thinning versus drilling) impact on implant rate? (2017) (9)
- Elaboration of a nomogram to predict nonsentinel node status in breast cancer patients with positive sentinel node, intraoperatively assessed with one step nucleic amplification: Retrospective and validation phase (2016) (9)
- Changes in the incidence, pattern of presentation and clinical outcome of early chronic lymphocytic leukemia patients using the 2008 International Workshop on CLL guidelines (2014) (9)
- Sentinel node biopsy in cutaneous melanoma: correlations between melanoma prognostic factors and sentinel node status. (2007) (9)
- Evaluation of Renal Function Under Controlled Hypotension in Zero Ischemia Robotic Assisted Partial Nephrectomy (2014) (9)
- Breast cancer, locally advanced and metastatic (2012) (9)
- Tremelimumab in combination with durvalumab in first or second-line mesothelioma patients: Safety analysis from the phase II NIBIT-MESO-1 study. (2017) (9)
- 1081MO Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trial (2020) (9)
- The utility of two prognostic models for predicting time to first treatment in early chronic lymphocytic leukemia patients: results of a comparative analysis. (2013) (9)
- Does low-molecular-weight heparin influence cancer-related mortality? (2006) (8)
- A simple score based on geriatric assessment predicts survival in elderly newly diagnosed chronic lymphocytic leukemia patients (2018) (8)
- Procedural Pain in Palliative Care: Is It Breakthrough Pain? A Multicenter National Prospective Study to Assess Prevalence, Intensity, and Treatment of Procedure-related Pain in Patients With Advanced Disease (2017) (8)
- Efficacy and safety of T-DM1 in the ‘common-practice’ of HER2+ advanced breast cancer setting: a multicenter study (2017) (8)
- IgA hypogammaglobulinemia predicts outcome in chronic lymphocytic leukemia (2019) (8)
- Antimicrobial Action of Nitens® Mouthwash (Cetyltrimethylammonium Naproxenate) on Multiple Isolates of Pharyngeal Microbes: A Controlled Study against Chlorhexidine, Benzydamine, Hexetidine, Amoxicillin, Amoxicillin-Clavulanate, Clarithromycin, and Cefaclor (2002) (8)
- Epirubicin plus docetaxel in metastatic breast cancer: escalating dose does not improve efficacy. A phase II study. (2004) (8)
- New aromatase inhibitors (Ais) as 1st-line endocrine therapy (ET) in metastatic breast cancer (MBC): A pooled analysis of 3238 women from 8 phase III trials (2005) (8)
- Treatment of resected non-small-cell lung cancer. (2005) (8)
- Clinical characteristics limiting the durability of humoral response to BNT162b2 in patients with solid cancer. (2021) (8)
- Prognostic significance of lymphocyte morphology in patients with advanced chronic lymphocytic leukemia treated with first line therapy of fludarabine + prednisone. (2002) (8)
- Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare system (2021) (8)
- Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study. (2020) (8)
- Prevalence of intestinal metaplasia in the distal esophagus in patients endoscopically suspected for short Barrett's esophagus. (2006) (8)
- A randomized, phase III study of fotemustine versus the combination of fotemustine and ipilimumab or the combination of ipilimumab and nivolumab in patients with metastatic melanoma with brain metastasis: the NIBIT-M2 trial. (2015) (8)
- Risk factors for a difficult intravenous access: A multicentre study comparing nurses' beliefs to evidence. (2019) (8)
- Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program (2018) (7)
- Two consecutive clinical trials on cisplatin (CDDP), hepatic arterial infusion (HAI), and I.V. 5‐fluorouracil (5‐FU) chemotherapy for unresectable colorectal liver metastases: An alternative to FUdR‐based regimens? (1991) (7)
- Radical surgery in rectal cancer patients: What does it mean today? (1991) (7)
- Is there a preferred dose of palonosetron? Results of an abstracted data (AD) meta-analysis (MA) of all eight randomized double-blind (RDB) studies and the impact on guideline considerations. (2009) (7)
- Ten years of experience with weekly chemotherapy in metastatic breast cancer patients: multivariate analysis of prognostic factors (2006) (7)
- The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients (2020) (7)
- Breakthrough cancer pain tailored treatment: which factors influence the medication choice? An observational, prospective and cross-sectional study in patients with terminal cancer (2018) (7)
- Correlation between Work Engagement and Burnout among Registered Nurses: an Italian hospital survey. (2019) (7)
- Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation (2013) (7)
- The magnitude of improvement in progression-free survival with targeted therapy in relapsed/refractory chronic lymphocytic leukemia based on prognostic risk category: a systematic review and meta-analysis (2018) (7)
- Early-onset versus late-onset Crohn's disease: An Italian cohort study (2020) (7)
- Should subgroup analysis of randomized clinical trials have a direct impact on clinical practice? (2007) (7)
- Preperitoneal Continuous Infusion of Local Anesthetics: What Is the Impact on Surgical Wound Infections in Humans? (2016) (7)
- Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program. (2018) (7)
- Identification of a variant hotspot in MYBPC3 and of a novel CSRP3 autosomal recessive alteration in a cohort of Polish cases affected by hypertrophic cardiomyopathy. (2020) (7)
- The Effect of Docosahexaenoic Acid and α-Lipoic Acid as Prevention of Bortezomib-Related Neurotoxicity in Patients With Multiple Myeloma (2019) (7)
- Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysis. (2020) (7)
- Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy (2020) (6)
- Systemic effect of radiotherapy before or after nivolumab in lung cancer: an observational, retrospective, multicenter study (2021) (6)
- A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. (2012) (6)
- HIV and decreased risk of multiple sclerosis: role of low CD4+ lymphocyte count and male prevalence (2017) (6)
- Italian cohort of nivolumab Expanded Access Programme (EAP): Preliminary data from a real-world population. (2016) (6)
- Activity of trastuzumab (t) beyond disease progression in HER2 over-expressing metastatic breast cancer (MBC) (2007) (6)
- Phase II study SECOMBIT (sequential combo immuno and target therapy study): A subgroup analysis with a longer follow-up. (2022) (6)
- Temozolomide Low-dose Chemotherapy in Newly Diagnosed Low-grade Gliomas: Activity, Safety, and Long-term Follow-up (2017) (6)
- A Multicenter Phase II Randomized Trial of Docetaxel/Gemcitabine versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Gruppo Oncologico Italia Meridionale Study (2011) (6)
- Bevacizumab plus chemotherapy in metastatic colorectal cancer patients treated in clinical practice. (2012) (6)
- Activity and toxicity of oxaliplatin and bolus fluorouracil plus leucovorin in pretreated colorectal cancer patients: a phase II study. (2005) (6)
- Bone Marrow Fibrosis and Early Hematological Response as Predictors of Poor Outcome in Azacitidine Treated High Risk-Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia. (2018) (6)
- Rapid decline of humoral response to two doses of BNT162b2 vaccine in patients with solid cancer after six months: The urgent need of the additional dose! (2022) (6)
- Long term efficacy and safety of Fludarabine, Cyclophosphamide and Rituximab regimen followed by 90Y-ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma (2015) (6)
- Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis (2021) (6)
- Nickel dermatitis from earrings 15 years after EU directive implementation: a clinical‐epidemiological study and a market survey in Rome, Italy (2019) (6)
- Chemotherapy-induced amenorrhea in early breast cancer. (2006) (6)
- Comparative Analysis of CEA and SCC Serum Markers with IAP in Human Lung Cancer (1989) (6)
- Peripherally inserted central catheter, midline, and “short” midline in palliative care: Patient-reported outcome measures to assess impact on quality of care (2018) (6)
- Multicenter phase II trial of first-line docetaxel/gemcitabine in advanced breast cancer pretreated with adjuvant anthracyclines. (2009) (6)
- Adjuvant chemotherapy for bladder cancer: the chance for meta-analyses comparison. (2007) (6)
- Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study (2022) (6)
- Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study (2022) (6)
- 491P Neoadjuvant nivolumab in early stage colorectal cancer (2020) (6)
- Society for Melanoma Research 2015 Congress (2015) (6)
- High dose-intense chemotherapy alone or in combination with interleukin-2 for small cell lung cancer: a pilot study. (1994) (6)
- Prognostic models for chronic lymphocytic leukemia (CLL): a systematic review and meta-analysis (2020) (6)
- Chronic lymphocytic leukemia and prognostic models: A bridge between clinical and biological markers (2017) (6)
- Phase II multicenter trial of ipilimumab combined with fotemustine in patients with metastatic melanoma: The Italian Network for Tumor Biotherapy (NIBIT)-M1 trial. (2012) (6)
- A prognostic algorithm including a modified version of MD Anderson Cancer Center (MDACC) score predicts time to first treatment of patients with clinical monoclonal lymphocytosis (cMBL)/Rai stage 0 chronic lymphocytic leukemia (CLL) (2014) (6)
- Assessing Financial Toxicity in Patients With Cancer: Moving Away From a One-Size-Fits-All Approach. (2019) (5)
- Prospective evaluation of metabolic syndrome and its features in a single-center series of hematopoietic stem cell transplantation recipients (2018) (5)
- Time to first tumor progression as outcome predictor of a second trastuzumab-based therapy beyond progression in HER2-positive metastatic breast cancer (2008) (5)
- Magnitude of risks and benefits of the addition of bevacizumab (BEVA) to chemotherapy (CT) for patients (pts) with advanced breast cancer (ABC): Metaregression analysis of randomized trials (RCT). (2010) (5)
- Toxicity at 1 year after Stereotactic Body Radiotherapy in 3 Fractions for Localized Prostate Cancer. (2021) (5)
- Aromatase inhibitors in post-menopausal metastatic breast carcinoma (2007) (5)
- Disease-free survival (DFS) as surrogate end point for overall survival (OS) in adjuvant aromatase inhibitors (AIs) trials for breast cancer (BC): Meta-analysis of 10 randomized clinical trials (RCTs) exploring the magnitude of the benefit (2007) (5)
- Peripheral lymphocyte subset counts predict antibody response after SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients: Results from the Vax-On-Profile study (2022) (5)
- Low‐dose alemtuzumab in refractory/relapsed chronic lymphocytic leukemia: Genetic profile and long‐term outcome from a single center experience (2015) (5)
- mRNA COVID‐19 vaccines in patients with chronic lymphocytic leukemia: A systematic review and meta‐analysis (2021) (5)
- Cost‐effectiveness in transient hypocalcemia post‐thyroidectomy (2019) (5)
- Randomized intermittent or continuous panitumumab plus FOLFIRI (FOLFIRI/PANI) for first-line treatment of patients (pts) with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): The IMPROVE study. (2022) (5)
- Six month immunogenicity of COVID-19 mRNA-BNT162b2 vaccine in actively treated cancer patients: updated results of the Vax-On study (2021) (5)
- Clinical and Immunological Outcomes in High-Risk Resected Melanoma Patients Receiving Peptide-Based Vaccination and Interferon Alpha, With or Without Dacarbazine Preconditioning: A Phase II Study (2020) (5)
- Medium-large polyps of the colon: a contribution for their clinical profile and a proper surveillance. (1997) (5)
- Italian nursing students' attitudes towards care of the dying patient: A multi-center descriptive study. (2021) (5)
- Factorial design for randomized clinical trials. (2006) (5)
- Comparison of venetoclax plus rituximab with B-cell receptor inhibitors in patients with relapsed/refractory chronic lymphocytic leukemia: a systematic review and network Meta-analysis (2019) (5)
- HER2/neu expression and hormonal therapy in early breast cancer: can muddy waters become clear? (2004) (5)
- Antineoplastic treatment class modulates COVID-19 mRNA-BNT162b2 vaccine immunogenicity in cancer patients: a secondary analysis of the prospective Vax-On study (2021) (5)
- Current status of targeted agents in advanced pancreatic cancer (APC): A pooled analysis of 2,361 patients (pts) enrolled in six phase III trials. (2006) (5)
- Thermal load effects on side plates of superyachts (2017) (5)
- O-120 Pooled-analysis of 6494 patients in 12 trials (1994–2004)receiving post-operative adjuvant chemotherapy in non-small cell lung cancer: Analyzing the magnitude of benefit in survival (2005) (5)
- mRNA-COVID19 Vaccination Can Be Considered Safe and Tolerable for Frail Patients (2022) (5)
- Combined hyperfractionated radiotherapy and protracted infusion chemotherapy in bladder cancer for organ preservation. (1998) (5)
- Short course hypofractionated whole breast irradiation after conservative surgery: a single institution phase II study (2017) (5)
- Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer (2021) (5)
- Diabetes and diabetic retinopathy in patients undergoing cataract surgery: a prevalence study—DiCat study report #2 (2020) (5)
- Hot-flashes in breast cancer survivors: effectiveness of low-dosage fluoxetine. A pilot study. (2005) (5)
- A qualitative analysis and development of a conceptual model assessing financial toxicity in cancer patients accessing the universal healthcare system (2020) (5)
- Thermochemotherapy for soft tissue sarcomas. (1991) (4)
- Features and organization of Pain Centers in the Lazio Region, Italy, in 2011. (2014) (4)
- NEURO/MEDICAL ONCOLOGY (2013) (4)
- Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three‐factor model (2022) (4)
- H16Clinical outcome of platinum/etoposide treated large cell neuroendocrine carcinomas of the lung according to the type of radiotherapy received: a single institution analysis (2015) (4)
- Flow cytometric analysis of DNA content and cell kinetics in colorectal carcinoma. (1993) (4)
- Increase of immunoglobulin A during ibrutinib therapy reduces infection rate in chronic lymphocytic leukemia patients (2020) (4)
- Cisplatin-induced peripheral neurotoxicity: relationship to dose intensity. (1991) (4)
- Long Term Survival and Immunological Correlates in Metastatic Melanoma Treated with Ipilimumab at 10 Mgs within an Expanded Access Program (2012) (4)
- Fludarabine , araC , novantrone and dexamethasone ( FAND ) in previously treated chronic lymphocytic leukemia patients (2002) (4)
- Peritoneal carcinomatosis from ovarian epithelial primary: combined aggressive treatment. (2009) (4)
- P3.02c-095 Italian Nivolumab Expanded Access Programme: Efficacy and Safety Data in Squamous Non-Small Cell Lung Cancer Patients: Topic: IT Clinical (2017) (4)
- Retrospective study evaluating the performance of a first-trimester combined screening for trisomy 21 in an Italian unselected population. (2014) (4)
- Gemcitabine-based polychemotherapy for advanced pancreatic cancer (APC): Is it ready for prime time? A pooled analysis of 3,682 patients (pts) enrolled in 12 phase III trials. (2006) (4)
- Nanoparticle albumin-bound paclitaxel/liposomal-encapsulated doxorubicin in HER2-negative metastatic breast cancer patients. (2020) (4)
- Potentiation of humoral response to the BNT162b2 vaccine after the third dose in patients with solid cancer (2022) (4)
- Efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg (2014) (4)
- Major bleedings in the comparisons between low-molecular weight heparin versus oral anticoagulant therapy for venous thromboembolism. (2007) (4)
- Surrogate endpoints for overall survival (OS) in advanced pancreatic cancer (APC): Analysis of randomized clinical trials (RCTs) exploring gemcitabine (G)-based combinations (2007) (4)
- Ibrutinib as initial therapy in chronic lymphocytic leukemia: A systematic review and meta‐analysis (2020) (4)
- MA 10.06 Real-World Results in Non-Squamous Non-Small Cell Lung Cancer Patients: Italian Nivolumab Expanded Access Program (2017) (4)
- Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-Remitting Multiple Sclerosis (2020) (4)
- Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis (2020) (4)
- A Clue to Better Select Chronic Lymphocytic Leukemia Patients with Optimal Response to BNT162b2 mRNA COVID-19 Vaccine (2021) (3)
- ERAS program adherence-institutionalization, major morbidity and anastomotic leakage after elective colorectal surgery: the iCral2 multicenter prospective study (2021) (3)
- Chronomodulated (chrono) infusion of 5-fluorouracil (5-FU) and 1-folinic acid (FA) in 91 patients (pts) with metastatic colorectal cancer: the Regina Elena Cancer Institute experience (1999) (3)
- Personality, inner experience and compliance in advanced cancer patients treated with external pumps. (1995) (3)
- Factors influencing diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) in pancreatic and biliary tumors (2021) (3)
- Refinement & validation of rectal wall dose volume objectives for prostate hypofractionation in 20 fractions (2020) (3)
- Double-Blind Randomized Phase 3 Study Comparing a Mixture of Natural Ingredients Versus Placebo in the Prevention of Acute Mucositis During Chemoradiation Therapy for Head and Neck Cancer (2015) (3)
- A Prospective Study Assessing the Post-Prostatectomy Detection Rate of a Presumed Local Failure at mpMR with Either 64CuCl2 or 64CuPSMA PET/CT (2021) (3)
- New aromatase inhibitors (AIs) as 2nd-line endocrine therapy (ET) in metastatic breast cancer (MBC): A comprehensive review of 5832 women from 14 phase III trials. (2004) (3)
- Do biologic parameters affect the time to first treatment of clinical monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia Rai stage 0? Results of a prospective analysis. (2015) (3)
- Abstracts (2019) (3)
- Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial. (2019) (3)
- Molecular genetic alterations in egfr CA-SSR-1 microsatellite and egfr copy number changes are associated with aggressiveness in thymoma. (2016) (3)
- Current status of targeted agents (TA) in advanced pancreatic cancer (APC): Meta-analysis of randomized clinical trials (RCT) (2008) (3)
- Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third study (2022) (3)
- Meta-analysis of the randomized comparisons between low-molecular weight heparin (LMWH) with oral anticoagulants (OA) for the long-term treatment of symptomatic venous thromboembolism (VTE): no difference in cancer-related mortality (2005) (3)
- The unmet need for oncofertility preservation in women: Results of a survey by different oncological specialists in Lazio, Italy. (2019) (3)
- THE UTILITY OF A PROGNOSTIC INDEX FOR PREDICTING TIME TO FIRST TREATMENT ( TFT ) IN EARLY CHRONIC LYMPHOCYTIC LEUKEMIA ( CLL ) : THE GIMEMA ( Gruppo Italiano Malattie EMatologiche dell ' Adulto ) EXPERIENCE (2009) (3)
- Erratum to: Elaboration of a nomogram to predict nonsentinel node status in breast cancer patients with positive sentinel node, intraoperatively assessed with one step nucleic amplification: Retrospective and validation phase (2017) (3)
- Tremelimumab and durvalumab (MEDI4736) combination for first and second-line treatment of mesothelioma patients: The NIBIT-MESO-1 study. (2016) (3)
- Frail Phenotype in Patients With Inflammatory Bowel Disease. (2022) (3)
- Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts (2018) (3)
- Neutrophil-to-lymphocyte ratio, Factor VIII and Antithrombin III: inflammatory-clotting biomarkers in glioma (2021) (3)
- Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2− Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series † (2020) (3)
- Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. (2018) (3)
- Efficacy and tolerability of very low-volume bowel preparation in patients with inflammatory bowel diseases (2021) (3)
- Abstract LB-226: mTOR inhibition by Temsirolimus as second-line treatment for advanced RCC: The Medical optimization of Torisel® (MoTOR) phase II trial by the Italian Kidney Cancer Group (GIR) (2012) (3)
- Erratum to: Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma (2014) (3)
- Sequential docetaxel followed by epirubicin-vinorelbine as first-line chemotherapy in advanced breast cancer. (2005) (3)
- The abscopal effect: efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg (2013) (3)
- High-dose chronomodulated infusion of 5-fluorouracil (5-FU) and folinic acid (FA) (FF5–16) in advanced colorectal cancer patients (2004) (3)
- Real-World Data of Nivolumab in Classical Hodgkin Lymphoma: Results from the Italian Expanded Access Programme (2017) (3)
- Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and (2010) (3)
- Impact of a goal-directed fluid therapy on length of hospital stay and costs of hepatobiliarypancreatic surgery: a prospective observational study. (2018) (2)
- Hepatic arterial infusion chemotherapy for unresectable colorectal liver metastases: A twelve-year experience (1995) (2)
- Adjuvant LH-RH agonists for premenopausal early breast cancer: A meta-analysis of randomized clinical trials (RCTs) exploring the magnitude of the disease-free and overall survival (DFS/OS) benefit (2007) (2)
- Ipilimumab and Stereotactic Radiosurgery with CyberKnife® System in Melanoma Brain Metastases: A Retrospective Monoinstitutional Experience (2021) (2)
- The prevalence of musculoskeletal disorders and low back pain among Italian nurses: an observationalstudy (2020) (2)
- 1142 Neo-adjuvant M-VAC chemotherapy and bladder preservation for muscle infiltrating transitional cell carcinoma (TCC) of the bladder (1995) (2)
- Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy: what is the appropriate use of filgrastim? (2006) (2)
- BEAM vs FEAM high-dose chemotherapy: retrospective study in lymphoma patients undergoing autologous stem cell transplant (2018) (2)
- Coagulation activation and cerebral hypoperfusion in relapsing-remitting multiple sclerosis (2019) (2)
- Hypogammaglobulinemia in Chronic Lymphocytic Leukemia: A Predictor of Outcome? (2017) (2)
- Lenograstim 5 µg/kg is not superior to biosimilar filgrastim 10 µg/kg in lymphoma patients undergoing peripheral blood stem cell mobilization after chemotherapy: preliminary results from a prospective randomized study (2018) (2)
- Improved local control and survival with the “sandwich” technique of pelvic radiotherapy for resectable rectal cancer (1994) (2)
- Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: Pooled-analysis of 8,794 patients. (2006) (2)
- Assessing two meta-analysis (MA) methods: Individual patient data-based (IPD) versus literature-based abstracted data (AD) in 10 MA including 37,002 patients (pts)-Are there differences of concern? (2011) (2)
- MA 19.02 Tremelimumab plus Durvalumab in First- or Second-Line Mesothelioma Patients: Final Analysis of the NIBIT-MESO-1 Study (2017) (2)
- Abstract CT270: A randomized, multi-center, phase II study of nivolumab combined with ipilimumab and guadecitabine or nivolumab combined with ipilimumab in melanoma and NSCLC patients resistant to anti-PD-1/-PD-L1: The NIBIT-ML1 Study (2020) (2)
- Nectin-4 and DNA mismatch repair proteins expression in upper urinary tract urothelial carcinoma (UTUC) as a model for tumor targeting approaches: an ImGO pilot study (2022) (2)
- Catheter-associated thrombosis: thromboprophylaxis for cancer patients who carry factor V Leiden? (2006) (2)
- Pembrolizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: Analysis of Prognostic Factors of Outcomes. (2021) (2)
- LBA41 Phase II study SECOMBIT (sequential combo immuno and target therapy study): 4-years OS data and preliminary biomarkers evaluation (2022) (2)
- Abstract P5-11-18: Real-world evidence of efficacy and activity of palbociclib plus endocrine therapy and post-progression treatments in HR+/HER2- metastatic breast cancer patients: The PALPract study (2020) (2)
- Multimodal pathway for brain tumor‐related epilepsy patients: Observational study (2020) (2)
- Comparison of Two Questionnaires on Informed Consent in "Marginal" Donor Liver. (2016) (2)
- Looking for a better measure of the benefit in clinical trials: a never-ending journey. (2020) (2)
- Looking for a Simplified Diagnostic Model to Identify Potentially Lethal Cases of Prostate Cancer at Initial Diagnosis: An ImGO Pilot Study (2022) (2)
- 16TiPA phase II study combining tremelimumab and durvalumab (MEDI4736) immunomodulating antibodies in mesothelioma patients: The NIBIT-MESO-1 study (2015) (2)
- American Society of Colon and Rectal Surgeons 91st Annual Convention Podium and Poster abstracts (1992) (2)
- LBA82 Influenza-like illness and SARS-Cov-2 in the multicenter, prospective, observational INVIDIa-2 study (INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: A transversal challenge): A FICOG study (2020) (2)
- MP55-11 DEVELOPMENT AND EXTERNAL VALIDATION OF NOMOGRAMS PREDICTING DISEASE-FREE AND CANCER SPECIFIC SURVIVAL AFTER RADICAL CYSTETCOMY (2014) (2)
- Could a biomarkers-based patients' selection help to plan a clinical trial with targeted agents (TA) for metastatic renal cell carcinoma (mRCC)? Interaction and power analysis of randomized trials (RCTs). (2013) (2)
- Preliminary cytogenetic and pharmacogenomic analysis of muscle-invasive transitional-cell carcinoma (TCC) of the bladder in patients (pts) enrolled in the Italian National Research Council (CNR) phase III randomized trial comparing adjuvant cisplatin-gemcitabine (PG) vs observation (OBS) after radic (2005) (2)
- [The impact of Reiki on side effects in patients with head-neck neoplasia undergoing radiotherapy: a pilot study]. (2017) (2)
- Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy : Italian multicenter study (2)
- Re: Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. (2007) (2)
- A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation (2021) (2)
- Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials. (2016) (2)
- A 17-Gene Expression Signature for Early Identification of Poor Prognosis in Clear Cell Renal Cell Carcinoma (2021) (2)
- Capecitabine (CAP) versus 5-fluorouracil (FU) in combination with oxaliplatin (OX) as 1st-line chemotherapy (CT) for advanced colorectal cancer (ACRC): Meta-analysis of randomized clinical trials (RCT) (2008) (2)
- Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis (2020) (2)
- Measuring financial toxicity of cancer in the Italian health care system: Initial results of the patient reported outcome for fighting financial toxicity of cancer project (proFFiT) (2019) (2)
- Adherence to Oral Endocrine Therapy in Women with Breast Cancer: A Mixed Method Study (2016) (2)
- Hyperthermic antiblastic perfusion in the treatment of locoregional spreading limb melanoma. (2003) (2)
- The role of the administration time of prophylactic antibiotic therapy in colorectal cancer surgery: a review of 6,069 patients from 36 randomized clinical trials. (1993) (1)
- Immunotherapy discontinuation and outcome: A multicenter real-life experience. (2019) (1)
- PD-L1+ neutrophils as novel biomarkers for stage IV melanoma patients treated with nivolumab (2022) (1)
- A01*Italian cohort of nivolumab Expanded Access Programme (EAP): efficacy and safety data from a real-world population (2016) (1)
- Early DMO: a predictor of poor outcomes following cataract surgery in diabetic patients. The DICAT-II study (2021) (1)
- Real-life effectiveness of T-DM1 in heavily pretreated HER2-positive advanced breast cancer patients: An Italian observational study. (2016) (1)
- [Utility of endoscopic follow-up after resection of colorectal cancer]. (2002) (1)
- The Prognostic Value of the Size and the Sub-Site of the Local Failure at DCE-MRI before Salvage Radiotherapy for Prostate Cancer (2022) (1)
- Setting the standard for advanced pancreatic ductal adenocarcinoma (A-PDAC) in 2010: Meta-regression and power analysis of phase III randomized clinical trials (RCT) evaluating gemcitabine (GEM) in combination with cisplatin (CIS), oxaliplatin (L-OHP), or capecitabine (CAP). (2010) (1)
- Abstract 4017: Anti-tumor activity of a BRAF inhibitor and IFNα combination in BRAF mutant melanoma (2016) (1)
- Adjuvant chemotherapy (AC) for muscle-invasive bladder cancer: A pooled analysis from phase III studies (2005) (1)
- A Prospective Study Evaluating Health-Related Quality of Life Following a Multimodal Treatment for Colorectal Cancer (2022) (1)
- The tissue CEA, TPA, and CA 19.9 in colorectal cancer patients: preliminary results of a quantitative study (1988) (1)
- Preoperative nivolumab in patients(pts) with locally advanced colon cancer (T3 or T4): A window-of-opportunity study (NICOLE). (2018) (1)
- Low Frequency of Acute Pancreatitis in Hospitalized COVID-19 Patients. (2021) (1)
- Antiseizure medication in patients with Glioblastoma- a collaborative cohort study (2021) (1)
- P.07.3 MAINTENANCE OF CLINICAL REMISSION IN IBD PATIENTS AFTER DISCONTINUATION OF ANTI-TNF AGENTS, AN ITALIAN EXPERIENCE (2016) (1)
- Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use (2012) (1)
- P3.08-04 OMEGA, A Randomized Trial of Local Ablative Therapy Vs. Conventional Treatment in Oligometastatic NSCLC – Trial in Progress (2018) (1)
- The Magnitude of Improvement in Progression-Free Survival with Targeted Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia Based on Genetic Risk: A Systematic Review and Meta-Analysis (2018) (1)
- Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme (2013) (1)
- Chronic Non-cancer Pain Management in a Tertiary Pain Clinic Network: a Retrospective Study (2022) (1)
- Safety of outpatient stem cell mobilization with low‐ or intermediate‐dose cyclophosphamide in newly diagnosed multiple myeloma patients (2021) (1)
- Serum BAFF (B-Cell Activating Factor of the TNF Family) Compared with Immunoglobulin Heavy-Chain Mutation Status, ZAP-70 and CD38 as a Predictor of Time to First Treatment in Early B-Cell Chronic Lymphocytic Leukemia. (2007) (1)
- Role of Pregabalin in Treatment of Polyneuropathy in Multiple Myeloma Patients: A Retrospective Study. (2019) (1)
- Hormonal adjuvant treatment plus radiotherapy versus exclusive radiotherapy in locally advanced prostate cancer: Pooled analsys of 6 randomized trials. (2006) (1)
- Ibrutinib in patients over 80 with chronic lymphocytic leukemia: a multicenter Italian cohort. (2022) (1)
- 2022-RA-972-ESGO Quality of life in patients with advanced ovarian cancer after primary debulking surgery versus neoadjuvant chemotherapy: results from the randomized SCORPION Trial (2022) (1)
- Palbociclib-fulvestrant (PALBO-FUL) and everolimus -exemestane (EVE-EXE) for second line hormonal treatment (HT) of metastatic breast cancer (MBC) with lobular histology: A propensity score matched analysis of a multicenter ‘real-world’ patients (pts) series (2019) (1)
- Bio-pathological factors of prognostic value in colorectal adenocarcinomas. (2003) (1)
- Major Differences in Lymphocyte Subpopulations Between Cerebrospinal Fluid and Peripheral Blood in Non-Hodgkin Lymphoma Without Leptomeningeal Involvement: Flow Cytometry Evidence of a Cerebral Lymphatic System (2021) (1)
- P659: IBRUTINIB IN OVER-EIGHTIES PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A MULTICENTER ITALIAN COHORT (2022) (1)
- EP08.01-030 Nivolumab+Ipilimumab Vs Platinum-Based CT+Nivolumab In Advanced Lung Squamous-Cell Carcinoma: The Randomized SQUINT Trial (2022) (1)
- FGFR2 fusion protein-driven mouse models of intrahepatic cholangiocarcinoma unveil a necessary role for Erk signaling (2020) (1)
- Some considerations about the value based pricing in oncology: an analysis on metastatic first line medicinal products (2016) (1)
- Identification of a miRNA-based non-invasive predictive biomarker of response to target therapy in BRAF-mutant melanoma (2022) (1)
- N-methylformamide affects spontaneous metastases of 3LL lines and increases natural killer activity of tumor-bearing mice (1990) (1)
- A prospective study assessing the pattern of response of local disease at DCE-MRI after salvage radiotherapy for prostate cancer (2022) (1)
- EP-1392: The abscopal effect:efficacy of radiotherapy in patients on progression after ipilimumab 3 mg/kg (2016) (1)
- Abstract P4-21-11: T-DM1 in HER2 positive advanced breast cancer patients: Real world practice from a multicenter observational study (2017) (1)
- Targeted agents (TA) for advanced solid tumors (AST): What is the likelihood of being helped or harmed (LHH)? Assessing the clinical impact of therapies with FDA/EMEA approval. (2013) (1)
- Immune-related adverse events correlate with clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with nivolumab in the Italian expanded access programme (2018) (1)
- 24 Nivolumab serum concentration in metastatic melanoma patients could be related to anti-tumor activity gene and outcome (2021) (1)
- Association between Helicobacter pylori infection and vulvar lichen sclerosus: a clinical comparative study (2018) (1)
- Post-Progression Treatments after Palbociclib plus Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer Patients: What Is the Better Choice? (2021) (1)
- Serum CD26 (Dipeptidyl Peptidase IV, DPP IV) compared with Immunoglobulin Heavy-Chain Mutation Status, ZAP-70 and CD38 as a Predictor of Time to First Treatment in Early B-CELL Chronic Lymphocytic Leukemia (2008) (1)
- Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters (2022) (1)
- Meta-analysis of adjuvant trastuzumab for early breast cancer: Cardiotoxicity and brain metastases incidence (2007) (1)
- Outcome of patients (pts) with brain metastases (BMs) from HER2-positive breast cancer (BC) treated with lapatinib plus capecitabine (LC). (2010) (1)
- PFS to predict long-term OS after first-line treatment for advanced renal cell carcinoma (aRCC): Correlation and power analysis of randomized trials (RCT). (2012) (1)
- Attrition bias: Does the benefit of targeted agents (TA) increase the more we search for a selection biomarker? Meta-regression analysis of randomized clinical trials (RCTs) in advanced non-small cell lung and colorectal cancer (NSCLC/CRC). (2011) (1)
- Correlation between BRAF mutational status and clinical response to pembrolizumab in advanced melanoma patients (2015) (1)
- FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort (2013) (1)
- Fractional incorporation of radionucleotides, a marker of in vitro tumor cell chemosensitivity in colorectal cancer. (1991) (1)
- Utilità di un follow-up endoscopico nei pazienti resecati per cancro del colon retto (2002) (1)
- PO-0741: Ipilimumab and stereotactic radiosurgery with cyberknife in melanoma brain metastases (2017) (1)
- IgD multiple myeloma a descriptive report of 17 cases: survival and response to therapy (2012) (1)
- Palliative care organization and staffing models in residential hospices: Which makes the difference? (2021) (1)
- Impact of taxanes in association with anthracyclines in 1st line chemotherapy for metastatic breast cancer (MBC): Comprehensive review of 2805 patients in 7 phase III trials. (2004) (1)
- Expression of CD73 on MDSCs and CD8+/PD-1+ cells as new possible biomarkers for advanced melanoma patients treated with nivolumab (2018) (1)
- 1725 Cancer patients' knowledge about totally implantable access port: A randomized controlled study (2015) (1)
- Is the International Prognostic INDEX for CLL (CLL-IPI) Useful to Predict Time to First Treatment of Patients with EARLY Disease? Results of a Prospective Multicenter Analysis (2015) (1)
- 19TiPA phase Ib study combining the second-generation DNA hypomethylating agent (DHA) guadecitabine (SGI-110) and ipilimumab in patients with metastatic melanoma: The NIBIT-M4 Study (2015) (1)
- Number of resected versus involved lymph-nodes as prognostic factor for survival and recurrence in early non-small cell lung cancer (NSCLC) (2008) (0)
- 2022-RA-1301-ESGO The impact of hospital surgical volume on survival in early-stage cervical cancer treated with radical hysterectomy: a sub-analysis of the SCCAN study (2022) (0)
- Measuring financial toxicity of cancer in the Italian health care system: Initial results of the patient reported outcome for fighting financial toxicity of cancer project (proFFiT). (2019) (0)
- bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials (2010) (0)
- Ten-year experience with weekly chemotherapy in metastatic breast cancer patients: Multivariate analysis of prognostic factors. (2006) (0)
- Systemic effect of radiotherapy (RT) followed by programmed death 1 (PD-1) inhibitors in non-small-cell lung cancer (NSCLC). (2018) (0)
- Anaplastic lymphoma kinase immunohistochemistry scores do not predict sensitivity to crizotinib in fluorescence in situ hybridization-positive non-small cell lung cancer patients (2018) (0)
- Correction to: Chronic Non-cancer Pain Management in a Tertiary Pain Clinic Network: a Retrospective Study. (2023) (0)
- Self-monitoring versus standard monitoring of oral anticoagulation. (2007) (0)
- 1309 POSTER How Much is the Likelihood of Being Helped or Harmed (LHH) When Adopting Oral Targeted Agents (OTA) in the Treatment of Advanced Solid Tumours (AST) – Comprehensive Assessment of Their Clinical Overall Impact According to FDA/EMEa Regulatory Approvals (2011) (0)
- Brain metastases and ado-trastuzumab emtansine (TDM-1) treatment in HER2 positive metastatic patients: an Italian multicenter analysis. (2017) (0)
- Association of Hospital Surgical Volume With Survival in Early-Stage Cervical Cancer Treated With Radical Hysterectomy (2022) (0)
- P1.15-01 Radiotherapy (RT) and Nivolumab in Non-Small-Cell Lung Cancer (NSCLC): A Multicenter Real-Life Experience (2018) (0)
- 27P Clinical relevance of NGS analysis in endometrial cancer (EC) management (2022) (0)
- P1.01-53 Bone Metastases and Efficacy of Immunotherapy in Patients with Pretreated Advanced Non-Small-Cell Lung Cancer (NSCLC) (2018) (0)
- Contents Vol. 75, 2008 (2008) (0)
- A comparison of two questionnaires on Informed Consent for extended criteria liver donors. (2015) (0)
- MA 01.07 Lanreotide Maintenance in SCLC Expressing Somatostatine Receptors: Efficacy Results of Multicenter Randomized G04.2011 trial (2017) (0)
- Abstract P1-19-43: Palbociclib-fulvestrant (PALBO-FUL) and everolimus -exemestane (EVE-EXE) for second line hormonal treatment (HT) of metastatic breast cancer (MBC) with lobular histology: A propensity score matched analysis (2020) (0)
- Growth time and metastatic potential of the 3924A Morris hepatoma implanted in rat liver: Experimental model of a single tumor (1992) (0)
- The Real-Life Journey of Elderly Patients in Soft Tissue and Bone Sarcomas: A Retrospective Analysis from a Sarcoma Referral Center (2020) (0)
- The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis (2023) (0)
- Predictive and prognostic value of inflammatory markers in locally advanced rectal cancer (PILLAR) – A multicentric analysis by the Italian Association of Radiotherapy and Clinical Oncology (AIRO) Gastrointestinal Study Group (2023) (0)
- Standard Versus High Dose Lenograstim in Adults with Hematological Malignancies for Peripheral Blood Progenitor Cell Mobilization: Results of a Retrospective Study on Behalf of Rome Transplant Network. (2008) (0)
- Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical Settings (2023) (0)
- Biological markers to predict response to neoadjuvant chemotherapy (NCT) in patients with locally advanced breast cancer (LABC): Ready for prime time? (2011) (0)
- Leukotoxicity after moderately Hypofractionated radiotherapy versus conventionally fractionated dose escalated radiotherapy for localized prostate Cancer: a secondary analysis from a randomized study (2019) (0)
- Short course hypofractionated whole breast irradiation after conservative surgery: a single institution phase II study (2017) (0)
- Should non-anthracycline-based chemotherapy (Non-A) substitute anthracycline-based (A) when combined with taxanes (T) as 1st-line chemotherapy (CT) for advanced breast cancer (ABC)? Meta-analysis of randomized clinical trials (RCTs) balancing efficacy and toxicity (2008) (0)
- Back to the future: The impact of oestrogen receptor profile in the era of molecular endometrial cancer classification. (2023) (0)
- 1048P Molecular predictors of immunotherapy efficacy in lung squamous-cell carcinoma (LSCC): Results from the randomized prospective SQUINT trial (2022) (0)
- Serum Adiponectin Compared with ZAP-70, CD38 and Immunoglobulin Heavy-Chain Mutation Status as a Predictor of Time to First Treatment in Early B-Cell Chronic Lymphocytic Leukemia. (2006) (0)
- AF.130 EFFICACY AND TOLERABILITY OF VERY LOW VOLUME BOWEL PREPARATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES (2021) (0)
- 1870 Adherence to endocrine therapy in women with breast cancer in relation to socio-demographic data (2015) (0)
- Comparison between Time-Limited,Venetoclax-Based and Continuous Bruton Thyrosine Kinase Inhibitors-Based Therapy in the Upfront Treatment of Chronic Lymphocytic Leukemia (CLL):a Systematic Review and Network Meta-Analysis (2020) (0)
- CD73 activity and outcome of advanced melanoma patients treated with nivolumab (2018) (0)
- C-MYB, serum P-53M, genetic instability, labeling index and endoscopic findings in patients with adenoma or colorectal cancer. (2004) (0)
- OC-0766 Response of local disease at magnetic resonance after salvage radiotherapy for prostate cancer (2022) (0)
- Intermittent or continuous panitumumab (PAN) plus FOLFIRI for first-line treatment of patients (pts) with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC): A randomized phase II trial (IMPROVE). (2018) (0)
- Exclusion of SERUM Thymidine Kinase Does NOT Reduce the Predictive VALUE of a Comprehensive Prognostic INDEX in Chonic Lymphocytic Leukemia. Results of an External Validation on a Prospective Cohort of Patients with EARLY Disease (2014) (0)
- Multiple expression patterns of biopathological markers as possible predictors of response to adjuvant chemotherapy with high dose epirubicin and cyclophosphamide (HD EC) for high risk breast cancer (1997) (0)
- Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis (2020) (0)
- Cardiotoxicity of weekly trastuzumab (T) plus epirubicin (E) and paclitaxel (P) for HER2-positive locally advanced (LA) and/or metastatic (M) breast cancer (BC): A feasibility phase II study (2007) (0)
- A02*Clinical and pathological predictors of Advanced Breast Carcinoma with Luminal subtype (ABC-Lum) identifying prognostic ‘outliers’: multicenter retrospective analysis in the ‘real-world’ scenario (2015) (0)
- OP08.10: Modification of free‐beta HCG and PAPP‐A MoM in women with a previous miscarriage (2016) (0)
- Prognostic models predicting overall survival of chronic lymphocytic leukemia (CLL) patients treated with ibrutinib-based therapies: a systematic review and meta-analysis (2023) (0)
- Conservative Surgery in cT4 Breast Cancer: Single-Center Experience in the Neoadjuvant Setting (2023) (0)
- Should There Be a Preferred Serotonin Antagonist for Antiemetic Use in Chemotherapy for Breast Cancer? Using Two Meta-Analysis Methods To Determine Whether Common Dose Differences Affect Efficacy with the Serotonin Antagonist Palonosetron. (2009) (0)
- [Influenza vaccination in advanced cancer patients undergoing immunotherapy with anti-PD-1/PD-L1 immune checkpoint inhibitors: what data do we have for the clinical recommendation?] (2018) (0)
- Efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg (2014) (0)
- Correlation of HLA-B*35 and DRB1*11 alleles with a high risk of interstitial aseptic pneumonitis in cancer patients receiving PD-1/PDL1 immune-checkpoint blockade. (2020) (0)
- Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis (2021) (0)
- Procedural pain in the hospice setting in Italy: A multicentre prospective observational study (2016) (0)
- 6051 Balancing pros and cons of the addition of Bevacizumab (BEVA) to first-line chemotherapy (CT) for advanced/metastatic colorectal cancer (MCRC): Meta-analysis of randomized clinical trials exploring absolute benefits (2009) (0)
- Tailoring treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma: does it affect outcome? (2023) (0)
- Re: Mastectomy and oophorectomy by menstrual cycle phase in women with operable breast cancer. (2002) (0)
- Early switch to a docetaxel-cisplatin (DP) doublet allows higher conversion to response for patients (pts) with advanced NSCLC in stable disease (SD) after 2 courses of gemcitabine-cisplatin (GP): Preliminary results of a pilot study (2005) (0)
- Trastuzumab-related cardiotoxicity in setting outside clinical trials: A mono-institutional experience (2008) (0)
- A65Primary prophylaxis of neutropenia in women affected by breast cancer undergoing adjuvant chemotherapy with fec 100 +/- docetaxel: comparison of efficacy and tolerability between lenograstim and pegfilgrastim (2015) (0)
- Tumor response assessment in locally unresectable or metastatic soft tissue sarcoma (aSTS) patients (pts): A three-year Regina Elena Cancer Institute (IRE) experience with trabectedin therapy. (2013) (0)
- Analysis of phase I pharmacokinetic studies with targeted molecules based on gender and age. (2016) (0)
- Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations (2018) (0)
- Dynamic circulating tumor DNA (ctDNA) in monitoring trastuzumab deruxtecan (TDXd) activity for patients (pts) with advanced breast cancer: Preliminary results of a feasibility study. (2022) (0)
- Impact of previous corticosteroid exposure on outcomes of patients receiving immune checkpoint inhibitors for advanced non-small cell lung cancer: a retrospective observational study (2022) (0)
- The Integration of Efficacy and Safety Outcomes Identifies the Net Clinical Benefit of Targeted Agents in Upfront Therapy of Chronic Lymphocytic Leukemia: Results of Network Meta-Analysis (2022) (0)
- P2.14-02 TP53 Mutations Affect Sensitivity to Lorlatinib in ROS1 Positive NSCLC: Final Results of the PFROST Trial (2022) (0)
- The net clinical benefit of targeted agents in the upfront treatment of elderly/unfit chronic lymphocytic leukemia patients: Results of network meta‐analysis (2023) (0)
- Three-year disease-free survival (DFS) as surrogate end-point for predicting five-year overall survival (OS) benefit in adjuvant taxane-based chemotherapy for breast cancer (BC): Analysis of 10 randomized clinical trials (RCTs) (2007) (0)
- MD Anderson Cancer Center (MDACC) Score Adds Prognostic Information To The Distinction Between High COUNT Monoclonal B-CELL Lymphocytosis (HC-MBL) and RAI STAGE 0 Chronic Lymphocytic Leukemia (CLL) (2013) (0)
- Prevention of Bortezomib-Induced Peripheral Neuropathy in Newly Multiple Myeloma Patients Using Nervonic Acid, Curcuma Rizoma, and L-Arginine Compound: A Pilot Study (2022) (0)
- Combi-TED: a new trial testing Tedopi® with docetaxel or nivolumab in metastatic non-small-cell lung cancer progressing after first line. (2023) (0)
- Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients (2013) (0)
- The controversial role of variants in HAMP , BMP 2 , FTL and SLC 40 A 1 genes (2015) (0)
- P-0270 Impact of Kras and Braf Gene Mutation Status on Outcomes of Chemotherapy in Combination with Bevacizumab in Metastatic Colorectal Cancer (2012) (0)
- Comment on: Mastectomy and oophorectomy by menstrual cycle phase in women with operable breast cancer. Authors' reply (2002) (0)
- F07Italian observational study on T-DM1 in HER2 positive advanced breast cancer patients: real world effectiveness and safety (2016) (0)
- Neoadjuvant C hemotherapy a nd R adical S urgery V ersus Exclusive R adiotherapy i n L ocally A dvanced S quamous C ell Cervical C ancer: R esults F rom t he I talian M ulticenter Randomized S tudy (2002) (0)
- Neoadjuvant Chemotherapy and Radical Surgery Versus (2001) (0)
- Prognostic relevance of baseline neutrophils and derived neutrophil to lymphocyte ratio for ipilimumab-treated advanced melanoma patients. (2015) (0)
- Prospective Study Investigating the Efficacy and Safety of a Scalp Cooling Device for the Prevention of Alopecia in Women Undergoing (Neo)Adjuvant Chemotherapy for Breast Cancer (2022) (0)
- A Simple Score, Based on Geriatric Assessment, Predicts Survival in Elderly Newly Diagnosed Chronic Lymphocytic Leukemia Patients (2016) (0)
- Abstract P4-13-07: SEQUERPLUS: A multicenter real practice observational study investigating the endocrine-based (E) therapies sequential approach in hormonal receptor positive (HR+) HER2 negative (-) metastatic breast cancer (MBC) (2019) (0)
- Serum Insulinlike Growth Factor Is Not Elevated in Patients with Early B-Cell Chronic Lymphocytic Leukemia but Is Still a Prognostic Factor for Disease-Progression. (2004) (0)
- Efficacy and safety of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: A systematic review and network meta-analysis. (2023) (0)
- EPIDEMIOLOGY, GENETICS AND PATHOGENESIS A01 FAMILIAL MELANOMA AND MULTIPLE PRIMARY MELANOMA: ANALYSIS OF PREDISPOSING GENETIC MUTATIONS IN 190 PATIENTS (2021) (0)
- 2022-LBA-677-ESGO Distribution and prognostic role of BRCA status in elderly ovarian cancer patients (2022) (0)
- P660: SEROLOGIC RESPONSE TO THE SECOND AND THIRD DOSE OF THE SARS-COV-2 VACCINE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF A PROSPECTIVE, CENTRALIZED, MULTICENTER STUDY. (2022) (0)
- Elaboration of a nomogram to predict nonsentinel node status in breast cancer patients with positive sentinel node, intraoperatively assessed with one step nucleic amplification: Retrospective and validation phase (2016) (0)
- P1.07-018 Incidence of Brain Recurrence and Survival Outcomes in High-Grade Neuroendocrine Carcinomas of the Lung: Implications for Clinical Practice: Topic: Local Treatment (2017) (0)
- Abstracts of the 26th World Congress on Ultrasound in Obstetrics and Gynecology, Rome, Italy, 24-28 September 2016. (2016) (0)
- 104P Fast progression in high PD-L1 NSCLC treated with pembrolizumab in first-line: A prognostic scoring system based on clinical features (2021) (0)
- Does progression-free-survival (PFS) correlate with overall- and cancer-specific survival (OS/CSS) in randomized clinical trials (RCTs) exploring the addition of hormonal therapy (HT) to radiotherapy (RT) for early prostate cancer (EPC)? Analysis of six RCTs (2007) (0)
- Abstract LB-115: Baseline neutrophil to lymphocyte ratio as a selection criterion for ipilimumab treatment in metastatic melanoma patients (2015) (0)
- Chronic Lymphocytic Leukemia (CLL) in Parents and Children. (2006) (0)
- Correlation of nivolumab 480 mg Q4W with better survival than other nivolumab monotherapy schedule in metastatic melanoma patients. (2020) (0)
- Elaboration of a nomogram to predict non sentinel node status in breast cancer patients with positive sentinel node, intra-operatively assessed with one step nucleic acid amplification method (2015) (0)
- FCR (Fludarabine, Cyclophosphamide, Rituximab) Followed By 90yttrium Ibritumomab Tiuxetan for the Treatment of Relapsed Grades 1 and 2 Follicular Lymphoma. Long Term Efficacy and Safety Results of 9 Cases (2014) (0)
- Impact of single/dual HER2 inhibition and chemotherapy (CT) backbone upon pathologic complete response (pCR) in patients receiving neoadjuvant CT for operable/locally advanced breast cancer (O/LABC): A treatment-interaction analysis of randomized trials. (2012) (0)
- Serum BAFF (B-CELL Activating Factor Of The TNF Family) predicts time to First Treatment in Early B-CELL Chronic Lymphocytic Leukemia (2008) (0)
- 5031 Overall response rate (ORR) and clinical benefit (CB) as clinical indicators for the efficacy of sequential Aromatase Inhibitors (AIs) in 3rd line hormonal treatment (HT) for advanced breast cancer (ABC): pooled analysis of phase II studies (2009) (0)
- The predictive value of 18F-FDG PET/CT after ipilimumab for treatment response evaluation in metastatic melanoma patients (2018) (0)
- Do “pan-negative” never-smoker (NS) lung cancer patients (pts) represent a new distinct subgroup? Data from a single-institution experience. (2014) (0)
- Should we consider altering our patterns of care for elderly sarcoma patients? (2018) (0)
- Safety and immunobiological activity of guadecitabine sequenced with ipilimumab in metastatic melanoma patients: The phase Ib NIBIT-M4 study. (2019) (0)
- Cytoreductive surgery for advanced epithelial ovarian cancer in the poly(ADP-ribose) polymerase inhibitors era-Is it time for a new paradigm shift? A systematic review and meta-analysis. (2023) (0)
- Abstract P6-10-01: Evaluation of post-progression survival (PPS) in advanced breast cancer (ABC) according to treatment line: Correlation with PFS and OS in an unselected population (2013) (0)
- Demystifying the diagnostic criteria of indolent systemic mastocytosis (2021) (0)
- 7164 POSTER Adjuvant Treatment for Resected Renal Cell Carcinoma (RCC): Are All Strategies Equally Negative? Meta-analysis of Randomized Trials (RCTs) (2011) (0)
- Dynamic Changes of Peripheral NK Cells Predict Outcome in Patients with PD-L1 Positive Non-small-cell Lung Cancer Undergoing Immune Checkpoint Inhibitors as Second-line Therapy (2022) (0)
- Biomolecular, biochemical, and radiologic evaluation and safety of chemotherapy with bevacizumab in treatment of patients affected by mCRC. (2011) (0)
- Detection of Helicobacter pylori carriers by discriminant analysis of urea and pH levels in gastric uices (2004) (0)
- 27P ALK immunohistochemistry scores do not predict sensitivity to crizotinib in fluorescence in situ hybridization-positive non-small cell lung cancer patients (2018) (0)
- P18.06ZONISAMIDE AS ADD-ON ANTIEPILEPTIC DRUG IN PATIENTS WITH BRAIN TUMOR-RELATED EPILEPSY: PRELIMINARY DATA OF A PILOT STUDY (2014) (0)
- 1297PALK AND ROS1-POSITIVE LUNG ADENOCARCINOMA (LA) PATIENT OUTCOMES: A MONO-ISTITUTIONAL EXPERIENCE. (2014) (0)
- Is stool DNA multitarget testing an unreliable strategy for colorectal cancer screening? (2005) (0)
- Taxanes as neoadjuvant chemotherapy (NAC) for breast cancer (BC): Pooled-analysis of 3120 patients (Pts) enrolled in 10 randomized trials (RCTs) (2005) (0)
- P-0257 Bevacizumab Effectiveness in First-Line Treatment of Metastatic Colorectal Cancer, in Relation to Kras Expression and Metastatic Sites (2012) (0)
- Propensity score analysis investigating the role of hormonal maintenance (HM) for advanced breast carcinoma with luminal subtype (ABC-Lum): Implication for prognostic modeling, post-progression and conditional survival (PPS/CS). (2016) (0)
- ALTERED EXPRESSION OF FAS SYSTEM IN OVARIAN CARCINOMAS: CORRELATION TO CONVENTIONAL PROGNOSTIC PARAMETERS (2003) (0)
- Delayed antiemetic treatment for weekly chemotherapy: Overview of 275 patients enrolled in 6 phase II trials of vhemotherapy in metastatic breast vancer (2005) (0)
- Reply from the Authors (1996) (0)
- BOTH MD Anderson Cancer Center MODEL and German Score Work in Predicting Time to First Treatment in EARLY Chronic Lymphocytic Leukemia: Results of an External Validation Analysis (2012) (0)
- Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy (2012) (0)
- Benefit of chemotherapy after third line and evaluation of post-progression survival (PPS) in metastatic breast cancer (MBC): A single institution study. (2017) (0)
- A prospective study assessing the post-prostatectomy detection rate of a presumed local failure at mpMR with 18F-choline, 64Cu-Cl2 or 64Cu-PSMA PET/CT (2021) (0)
- How much is reasonable to expect about overall survival (OS) benefit when designing studies with new drugs for patients affected by castration resistant prostate cancer (CRPC)? Meta-analysis of 23 randomized clinical trials (RCT) including 17,640 patients. (2013) (0)
- 1576P Efficacy of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: A network meta-analysis (2022) (0)
- Author response for "Perampanel in brain tumor-related epilepsy: Observational pilot study" (2020) (0)
- Phase I-II trial of prolonged gemcitabine (G) infusion in combination with paclitaxel (P) in heavily-pretreated advanced breast cancer (ABC) patients (pts) (2008) (0)
- Disease-free survival (DFS) as surrogate end-point for overall survival (OS) in early breast cancer (EBC): Correlation may be different according to drugs and/or strategies tested (2008) (0)
- Nivolumab serum concentration in metastatic melanoma patients could be related to outcome and enhanced immune activity: a gene profiling retrospective analysis (2022) (0)
- Observational study on dietary habits and quality of life in patients with colorectal cancer. (2017) (0)
- THERMAL LOAD EFFECTS ON ALUMINUM LIGHT ALLOY PLATES WITH EPOXY COATINGS (2017) (0)
- First-line gefinitib (G) for advanced non-small cell lung cancer (NSCLC) patients (pts) harboring sensitizing epidermal growth factor receptor mutations (EGFR-M+): Meta-analysis of randomized trials (RCT) exploring the magnitude of benefits over chemotherapy (CT). (2010) (0)
- HIV and decreased risk of multiple sclerosis: role of low CD4+ lymphocyte count and male prevalence (2016) (0)
- P664: GRADING QUALITY OF EVIDENCE AND STRENGTH OF RECOMMENDATIONS FOR THE TREATMENT OF RELAPSED/REFRACTORY CLL. (2022) (0)
- P1-07-07: Assessing Two Methods of Meta-Analysis in Studies of Patients with Breast Cancer: Individual Patient Data-Based (IPD) Versus Literature Based Abstracted Data (AD) in 5 Meta-Analyses Including over 28,000 Patients. Are There Results Differences of Concern? (2011) (0)
- Usefulness of differential time to positivity between catheter and peripheral blood cultures for diagnosing catheter-related bloodstream infection: Data analysis from routine clinical practice in the intensive care unit. (2023) (0)
- Chordoma: A rare bone tumor: A single institutional experience on a case series of 23 patients. (2009) (0)
- Efficacy of ceritinib administered to patients with crizotinib-refractory, ALK-positive, advanced NSCLC within the Italian compassionate use program. (2017) (0)
- Dynamic changes in peripheral lymphocytes and antibody response following a third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients (2022) (0)
- Real-Rd - Real Life Italian Experience with Lenalidomide and Low-Dose Dexamethasone (Rd) As First Line Treatment of Newly-Diagnosed Multiple Myeloma Patients Not Eligible to Stem Cell Transplantation: Outcomes and Tolerability (2019) (0)
- 2022-RA-585-ESGO Come back to the future: the impact of estrogen receptor profile in the era of molecular endometrial cancer classification (2022) (0)
- Repurposing Chlorpromazine as add-on in the adjuvant phase of first-line glioblastoma therapeutic protocol in patients carrying hypo-/un-methylated MGMT gene promoter: RACTAC, a Phase II multicenter single arm clinical trial (2023) (0)
- Adjuvant treatment in elderly cancer patients: a multicenter real-life experience. (2017) (0)
- Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation (2022) (0)
- Abstract P1-17-02: Ado-trastuzumab emtansine (TDM-1) treatment and brain metastases in HER2 positive metastatic breast cancer patients: Final analysis of an italian multicenter study (2018) (0)
- Impact of Bone Marrow Fibrosis and Early Response on Outcome after Azacitidine Therapy in 94 Patients with Myelodisplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia (2016) (0)
- 79P ERLOTINIB EFFICACY IN PRETREATED EGFR WILD-TYPE CAUCASIAN PATIENTS: A MULTIVARIATE ANALYSIS IDENTIFIYNG FAVOURABLE PROGNOSTIC/PREDICTIVE FACTORS (2013) (0)
- Short-and Long-Term Effects of †̃ 86 Re1 , 1-Hydroxyethylidene Diphosphonate in the Treatment of Painful Bone Metastases (2006) (0)
- Retraction Note: Prognostic models for chronic lymphocytic leukemia (CLL): a systematic review and meta-analysis (2022) (0)
- Erratum to: Elaboration of a nomogram to predict nonsentinel node status in breast cancer patients with positive sentinel node, intraoperatively assessed with one step nucleic amplification: Retrospective and validation phase (2017) (0)
- Updated outcomes of previously irradiated non-small-cell lung cancer (NSCLC) patients (pts) receiving programmed death 1 (PD-1) inhibitors. (2018) (0)
- Ercc1 Mrna Expression and Kras Mutation Status In Egfr Wild Type (wt) Advanced Non-small Cell Lung Cancer (nsclc) Patients (2013) (0)
- The immersive experience of virtual reality during chemotherapy in patients with early breast and ovarian cancers: The patient’s dream study (2022) (0)
- VITAMIN D Insufficiency Affects Time to FIRST TREATMENT (TFT) In EARLY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) (2011) (0)
- Pre‐exposure prophylaxis with tixagevimab/cilgavimab in patients with chronic lymphocytic leukaemia treated with targeted agents (2023) (0)
- EP08.02-048 Crizotinib in ROS1+NSCLC: Long-term OS Analysis in Patients with Brain Metastases Included in the Phase II METROS Trial (2022) (0)
- P11.51 Repurposing the antipsychotic chlorpromazine for the treatment of glioblastoma multiforme (2019) (0)
- 132P Genomic profiling of primary and recurrent ovarian cancers: A retrospective single-center experience (2022) (0)
- Immune correlates of metastatic melanoma patients treated with ipilimumab in combination with fotemustine in the phase II NIBIT-M1 study (2013) (0)
- EXTENDED CRITERIA LIVER DONATION AND TRANSPLANT RECIPIENT CONSENT: THE EUROPEAN EXPERIENCE: 234 (2010) (0)
- Advanced colorectal cancer (ACC): impact of chronotherapy (chrono) on patients' (pts) quality of life (QoL) (1999) (0)
- Observational study on the effectiveness of the Dragon Boat in reducing the risk of incidence of lymphedema in women with breast cancer. (2017) (0)
- Subject Index Vol. 75, 2008 (2008) (0)
- Evaluation of the response to chemotherapy in patients affected with small cell lung cancer using discriminant analysis: a preliminary report. (1995) (0)
- A Treatment-Interaction Analysis Balancing Pathological Complete Responses (PCR) and Cardiotoxicity of Single-(S)/Dual-(D) HER2 Inhibition and Neoadjuvant Chemotherapy (CT) Backbone in Operable/Locally Advanced Breast Cancer (O/LABC) Patients (2012) (0)
- Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief Communication (2022) (0)
- Meeting abstracts (2003) (0)
- 2022-RA-723-ESGO Hormone replacement therapy in gynecological cancer survivors and BRCA mutation carriers: a MITO group survey (2022) (0)
- A49Phase I of weekly nab-paclitaxel in combination with weekly liposomal encapsulated doxorubicin as first-line treatment for HER2 negative metastatic breast cancer patients: preliminary results (2015) (0)
- 234P CDK 4/6 inhibitors (CDK4/6i) for metastatic breast cancer (mBC): The Likelihood of being Helped or Harmed (LHH) as a patient-centred tool to assess clinical impact and safety (2022) (0)
- 2028 ORAL Concomitant versus sequential chemo-radiotherapy for early breast cancer: meta-analysis of randomized clinical trials (RCTs) (2007) (0)
- Meta-analysis of the prognostic impact of TP53 co-mutations in EGFR-mutant advanced non-small-cell lung cancer treated with tyrosine kinase inhibitors. (2023) (0)
- Maintenance bevacizumab after first-line treatment in HER2-negative metastatic breast cancer patients. (2011) (0)
- A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation (2021) (0)
- Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer (2021) (0)
- ResearchMagnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer : meta-analysis of randomized clinical trials (2015) (0)
- Impact of epilepsy and its treatment on brain metastasis from solid tumors: A retrospective study (2022) (0)
- Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab (2017) (0)
- Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients (2020) (0)
- Stage III melanoma patients treated with radical lymphadenectomy: correlation between histopathological and biological parameters and influence on disease outcome (1997) (0)
- Nectin-4 and DNA mismatch repair proteins expression in upper urinary tract urothelial carcinoma (UTUC) as a model for tumor targeting approaches: an ImGO pilot study (2022) (0)
- MA05.07 Efficacy and Safety of Re-Treatment with Tremelimumab and Durvalumab Within the NIBIT-MESO-1 Study (2019) (0)
- Correction: Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation (2022) (0)
- A39Dose-finding study on a continuous dose of oral vinorelbine (VNR) in heavily pre-treated metastatic breast cancer (MBC) patients (pts) (2015) (0)
- Upfront Therapy with Ibrutinib Results in a Longer Progression-Free Survival Independently of IGHV Mutational Status and Del(11q) in CLL Patients. Results of a Comprehensive Review and Meta-Analysis (2019) (0)
- Reversibility of Frail Phenotype in Patients with Inflammatory Bowel Diseases (2023) (0)
- session F: genitourinary and gynaecologic cancer F1* A RANDOMIZED, PROSPECTIVE, PHASE 2 STUDY, WITH SORAFENIB (S) AND INTERLEUKIN-2 (IL-2) VERSUS S ALONE AS FIRST LINE TREATMENT IN ADVANCED RENAL CELL CANCER (RCC): ROSORC TRIAL (2009) (0)
- Small Trials for Meta-analysis: The Effect on Heterogeneity. (2010) (0)
- Ibrutinib in patients over 80 years old with CLL: a multicenter Italian cohort (2022) (0)
- Impact of radiotherapy (RT) in patients (pts) affected by locally advanced prostate cancer (LAPC) undergoing hormone treatment (HT): Meta-analysis of randomized trials (RCTs). (2011) (0)
- 232TiP Early acupuncture treatment of vasomotor symptoms and sleep disorders in breast cancer LHRHa induced menopause: AcuFLASH Study (2022) (0)
- The role of ' early phases ' : are traditional phase I studies with new drugs reliable ? (2015) (0)
- 2022-LBA-746-ESGO Implementation of a comprehensive cancer genome profiling programme into clinical practice: an italian experience in a referral centre for gynecological cancers (2022) (0)
- The Prognostic Value of DCE-MRI Findings before Salvage Radiotherapy after Radical Prostatectomy (2023) (0)
- EP09.01: The role of cytochrome P450 in nuchal translucency thickness: a preliminary study. (2016) (0)
- 377POVERALL PROGNOSIS OF ADVANCED BREAST CANCER (ABC) ACCORDING TO CHEMOTHERAPY (CT) TREATMENT LINES: CORRELATION ANALYSIS BETWEEN PROGRESSION-FREE-, POST-PROGRESSION- AND OVERALL- SURVIVAL (PFS, PPS AND OS). (2014) (0)
- A randomized trial on hepatic arterial CDDP and i.v. 5-FU in unresectable colorectal liver metastases (1999) (0)
- Atrial Fibrillation (AF) and Ibrutinib, a Monocentric Experience: Should Cardiological Evaluation be a Guide in Clinical Practice? (2017) (0)
- Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program (2022) (0)
- Idiopathic acute pancreatitis: a single-center investigation of clinical and biochemical features (2020) (0)
- Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts (2018) (0)
- 23P Impact of PDL1 expression on outcomes of patients with EGFR mutant NSCLC treated with EGFR TKIs: First results of the POET study (2023) (0)
- ABCB1, CYP3A5*3, and CYP3A4*1B SNPs and risk of toxicity with sunitinib treatment for mRCC. (2017) (0)
- Short-term (ST) versus long-term (LT) hormone treatment (HT) in combination with radiotherapy (RT) for locally advanced prostate cancer (LAPC): Meta-analysis of randomized trials (RCTs). (2009) (0)
- Effectiveness of a panel of sputum markers in smokers with and without COPD to detect pulmonary progression towards functional impairment (2020) (0)
- Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study (2023) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Diana Giannarelli?
Diana Giannarelli is affiliated with the following schools:
